Lijuan Yan

Dr. Lijuan Yan

orcid
Department of Anesthesiology, The First Affiliated Hospital ...

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
Lijuan YanLijuan Yan
Lijuan Yan
XWXiao Wang
Xiao Wang
ZCZhenyi Chen
Zhenyi Chen
NWNingning Wu
Ningning Wu
HLHao Li
Hao Li
BYBin Yang
Bin Yang
Introduction: Obese patients are susceptible to hypoxaemia during procedural sedation. Propofol combined with low-dose opioids is commonly used as a sedation strategy, but it can exacerbate hypoxaemia by causing cardiopulmonary depression and airway obstruction, especially in obese patients. Remimazolam, a novel ultra-short-acting benzodiazepine, has minimal accumulative effects and less cardiorespiratory depression. This study aims to evaluate the safety and efficacy of combining remimazolam tosilate with low-dose fentanyl as an alternative option for procedural sedation in obese patients undergoing gastroscopy. Methods and analysis: This randomised controlled trial (RCT) will be conducted in the Endoscopy Centre of the First Affiliated Hospital of Xiamen University, recruiting 174 participants scheduled for painless gastroscopy with a body mass index of 30–39.9 kg×m –2 . All patients will be randomly divided into two groups in a 1:1 ratio. The sedation strategy of the intervention group is remimazolam tosilate combined with fentanyl, while the control group is propofol combined with fentanyl. The primary outcome is the incidence of hypoxaemia and the secondary outcomes include the time to ambulation, need for airway manoeuvres and rescue sedation, sleep quality, the incidence of sedation failure, adverse events and the cost of sedatives. All statistical tests will be performed using IBM SPSS V.20.0 statistical software. A p value<0.05 is considered statistically significant. Ethics and dissemination: This RCT was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University (Scientific Research Ethics Review 2022, No.093). The results will be published in peer-reviewed journals. Trial registration number: ChiCTR2200067076.

18 July 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
XWXiao Wang
Xiao Wang
Lijuan YanLijuan Yan
Lijuan Yan
XZXiaodong Zhang
Xiaodong Zhang
XLXiang Liu
Xiang Liu
BYBin Yang
Bin Yang
Insomnia, affecting up to 30% of adults (typically 18–65 years), is characterized by GABAergic dysfunction and hyperarousal. This mini-review establishes three pivotal advances in insomnia therapeutics: Firstly, it is demonstrated that microbiota-gut-brain axis (MGBA) dysregulation is mechanistically central to insomnia, directly linking gut dysbiosis to vagal, hypothalamic-pituitary-adrenal (HPA), and γ-aminobutyric acid (GABA) axis dysfunction and neuroinflammation. Secondly, the present study documents the unique multitarget effects of electroacupuncture (EA), which have been shown to simultaneously normalize HPA axis activity, enrich GABA-producing microbiota, improve the vagal tone, and suppress neuroimmune activation. The aforementioned effects collectively resolve insomnia’s multifactorial etiology. Thirdly, clinical evidence confirms the sustained efficacy of EA to be comparable to that of hypnotics, yet with superior safety and durability. EA redefines therapeutic frameworks by integrating biological and neural interventions that are inaccessible to single-target approaches.

18 February 2024 in Heliyon
Verified
Journal Article
Open access
Lijuan YanLijuan Yan
Lijuan Yan
XWXiao Wang
Xiao Wang
ZZZuobing Zhang
Zuobing Zhang
ZLZhibin Li
Zhibin Li
LCLaiting Chi
Laiting Chi
LWLijuan Wang
Lijuan Wang
Pain is a major challenge in performing ultrasound-guided percutaneous microwave ablation (PMWA) of uterine myomas. Inadequate analgesia by local anesthetics hinders the possibility of conducting PMWA of uterine myomas in the Ambulatory Surgery Center (ASC) of the Department of Ultrasound. The superior hypogastric plexus (SHP) forms a suitable target for pain relief through the blockade, as it contains nociceptive afferent fibers from pelvic organs such as the uterus, rectum, and bladder. Superior hypogastric plexus block (SHPB) has demonstrated promise as an alternative treatment option for alleviating pelvic pain, reducing opioid consumption, and improving quality of life. This study aims to evaluate the efficacy of ultrasound-guided SHPB combined with conscious sedation as an alternative anesthesia option for ambulatory patients receiving ultrasound-guided PMWA of uterine myomas. This randomized controlled trial (RCT) will be carried out at the Department of Ultrasound, The First Affiliated Hospital of Xiamen University. Women scheduled for ultrasound-guided PMWA of uterine myomas will be eligible. 86 patients will be recruited and randomly assigned to either the intervention or control groups in a 1:1 ratio. The intervention group will undergo ultrasound-guided superior hypogastric plexus block (SHPB) combined with conscious sedation, while the control group will receive local anesthesia combined with conscious sedation. The primary outcome is the success rate of anesthesia, secondary outcomes include vasoactive drug consumption, acetaminophen consumption, sleep quality, sonographer satisfaction score, patient satisfaction score, the detained time in hospital, and adverse events. This RCT represents the inaugural effort to specifically evaluate the safety and efficacy of ultrasound-guided SHPB combined with conscious sedation in patients undergoing ultrasound-guided PMWA of uterine myomas and will provide valuable evidence and insight into the analgesic management of this ambulatory surgery. This study has been approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University (Scientific Research Ethics Review 2023, No. 139). The results will be submitted for publication in peer-reviewed journals.

14 September 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
Lijuan YanLijuan Yan
Lijuan Yan
XWXiao Wang
Xiao Wang
KDKairong Du
Kairong Du
YLYing Liang
Ying Liang
Introduction: Obese patients who undergo painless gastroscopy are particularly prone to suffer from upper airway obstruction, respiratory depression, and subsequent hypoxemia. Despite adequate preoxygenation, the incidence of hypoxemia remains high. Recently, inspiratory muscle training (IMT) has been considered to be a promising strategy to increase respiratory muscle strength and endurance with the attendant improvement of pulmonary function. However, it remains unclear whether IMT is associated with a lower rate of hypoxemia in obese patients during this sedative procedure. This study aims to investigate the effectiveness of IMT used in obese patients who are scheduled for selective painless gastroscopy.Methods and analysis: This prospective, randomized controlled trial (RCT) will enroll 232 obese patients with a body mass index (BMI) of 35–39.9 kg·m−2 who undergo painless gastroscopy at the First Affiliated Hospital of Xiamen University. Subjects will be randomly assigned to two groups with a 1:1 ratio. Participants in both groups will receive IMT for 4 weeks prior to gastroscopy. The intervention group will receive IMT with a load of 30% of the maximal inspiratory pressure (Pi(max)) in the first week, with an increase of 10% per week since the following week, while the counterparts in the control group will not receive any load during the 4-week IMT. The primary outcome is the incidence of hypoxemia during painless gastroscopy. Secondary outcomes include the need for airway maneuvers, blood pressure changes, sleep quality assessment, pro-inflammatory cytokines levels, and monitoring of adverse events.Discussions: The outcomes of this study will offer invaluable guidance for the clinical implementation of IMT as a potential non-invasive preventive measure. Additionally, it stands to enrich our comprehension of anesthesia management and airway-related challenges in obese patients undergoing procedural sedation, which we anticipate will further contribute to addressing the turnaround concerns within high-volume, swiftly paced ambulatory endoscopy centers.Ethics and dissemination: This study has been approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University (2022, No.091). The results will be submitted for publication in peer-reviewed journals.Trial registration number: China Clinical Trial Center (ChiCTR2200067041).

30 April 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
Lijuan YanLijuan Yan
Lijuan Yan
XWXiao Wang
Xiao Wang
XLXiang Liu
Xiang Liu
JCJiaying Cai
Jiaying Cai
ZZZuobing Zhang
Zuobing Zhang
BYBin Yang
Bin Yang
Introduction: Insomnia is a prevalent psychiatric disorder that significantly impacts mental and physical health. Emerging evidence suggests that gut microbiota, particularly γ-aminobutyric acid (GABA) producing bacteria, plays a critical role in the microbiome-gut-brain axis (MGBA), influencing sleep and mental states. Electroacupuncture (EA) has been shown to have favorable anti-insomnia effects. This research protocol outlines a randomized controlled trial (RCT) designed to investigate the efficacy of EA in modulating GABA levels via the MGBA to alleviate insomnia.Methods and analysis: The study will use glutamate (Glu) concentrations of p-chlorophenylalanine (PCPA) -induced insomnia rat model to examine whether EA at specific acupoints can increase GABA levels in the brain and plasma by enhancing the abundance of GABA-producing gut bacteria. A second experiment will transplant stool from insomnia rats into germ-free mice to evaluate the causal role of microbiota in insomnia pathology. Primary outcome measures include changes in GABA and Glu levels, data about the open field test, and gut microbiota composition.Discussion: This study will provide insights into the therapeutic mechanisms of EA targeting the MGBA in the treatment of insomnia and contribute to the development of novel therapeutic strategies.Ethics and dissemination: This study has been approved by the Laboratory Animal Center of Xiamen University (No. XMULAC20220100). The study findings will be submitted for publication in peer-reviewed academic journals.

17 September 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XWXiao Wang
Xiao Wang
Lijuan YanLijuan Yan
Lijuan Yan
JCJiaying Cai
Jiaying Cai
JWJianfei Wei
Jianfei Wei
ZZZuobing Zhang
Zuobing Zhang
BYBin Yang
Bin Yang
Background: Opioid-induced respiratory depression (OIRD) is a critical safety concern during ambulatory percutaneous liver tumor thermal ablation. Esketamine has been shown to offer a promising opioid-sparing alternative with the potential to provide respiratory stability benefits. We hypothesize that hepatic hilar nerve block (HHNB) combined with esketamine will reduce the incidence of respiratory depression when compared to HHNB in conjunction with fentanyl in this particular context.Methods: This single-center, prospective, double-blind, randomized controlled trial (RCT) will enroll patients undergoing ambulatory ultrasound-guided percutaneous liver thermal ablation. Patients will be randomly assigned to receive either intravenous esketamine 0.37 mg kg−1 (Intervention group) or intravenous fentanyl 1 μg·kg− (Control group). All subjects will receive a standardized premedication consisting of midazolam 0.03 mg kg−1 IV, followed by ultrasound-guided HHNB.Results and analysis: The primary outcome is the incidence of respiratory depression, defined as SpO2 55 mmHg. Secondary outcomes include the rate of anesthesia success, postoperative pain scores, and the consumption of remedial analgesia at 2, 6, and 24 h post-surgery. Additionally, satisfaction scores from both the sonographer and the patient are considered, along with any adverse events that may occur. The statistical analysis will utilize appropriate parametric/non-parametric tests for continuous data and chi-square/Fisher’s exact tests for categorical data (significance p < 0.05), using SPSS (v20.0) and R (v4.4.3; R Foundation) within the RStudio environment (v2024.12.1 + 563).Conclusion and discussion: This trial aims to provide Level I evidence comparing the respiratory depression risk between esketamine-based and fentanyl-based analgesia during HHNB-guided liver ablation. Should esketamine prove to be demonstrably superior in terms of respiratory safety, HHNB-esketamine has the potential to be a viable treatment option.